Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD

Lung Institute

Overview

The aim of this randomized, controlled crossover designed study is to compare the outcomes of receiving autologous, adult stem cells versus placebo among participants with chronic obstructive pulmonary disease (COPD). The study is limited to self-funded participants with a diagnosis of COPD. The study, along with others at the Lung Institute, have received full review and approval of an Institutional Review Board.

The purpose of the Lung Institute is to collect, minimally process, and administer a person's own stem cells and/or platelet rich plasma and deliver the product back to the patient same-day through an intravenous catheter. This study is limited to patients diagnosed with chronic obstructive pulmonary disease (COPD) and is a double-blinded prospective, cohort trial using cross-over methodology. The aim of this study is to determine if stem cell therapy is better than placebo among a group of patients with COPD. 50 participants will be recruited for each arm of the study. Cohort A will receive three days of cell therapy using the venous procedure (three consecutive days of blood harvest, cell separation and cell application). Cohort A will return in three months and receive three consecutive days of placebo. Cohort B will receive three consecutive days of placebo. Cohort B will return in three months and receive three consecutive days of cell therapy using the venous procedure.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

COPD Emphysema or COPD Chronic Bronchitis

Interventions

Treatment Then PlaceboPROCEDURE

Cohort A will receive stem cells/PRP infusion during round one then placebo of normal saline infusion during round two.

Placebo Then TreatmentPROCEDURE

Cohort B will receive placebo of normal saline infusion during round one then stem cells/PRP infusion during round two.

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients are included in treatment by self-referral and after consultation with a designated patient coordinator who determines initial eligibility, and then by the clinic nurse practitioner or physician of Lung Institute who determines final eligibility for inclusion. Patients must be diagnosed with chronic obstructive pulmonary disease (COPD) and be able to travel to the Dallas clinic location. Exclusion Criteria: * Patients who are unable to provide informed consent, pregnant patients, prisoners, non-English speakers, patients with a history of cancer within the past 5 years, patients with active tuberculosis or pneumonia. Patients without a documented COPD diagnosis are excluded.

Locations (1)

Lung Institute Dallas

Dallas, Texas, United States

Outcomes

Primary Outcomes

Change in Quality of Life Score

Change in QOL score from baseline to 3 months and 6 months following each treatment

Time frame: 3 months, 6 months following each treatment

Secondary Outcomes

Change in FEV1

Change in FEV1 from baseline to 6 months post-treatment

Time frame: 6 months following each treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.